Pharma companies are moving their Generative AI (GenAI) investments from pilot to production through exploration, experimentation, industrialisation/scaling, adoption, and monetisation.
In the pharmaceutical research field, the journey from laboratory to pharmacy shelf is fraught with challenges, such as the high failure rates and increasing costs of clinical trials.
With the hype around generative AI (GenAI), there is an increasing demand to explore its capabilities across pharma and MedTech companies, as well as contract research organisations.
Drug development industry stakeholders recognise there is no one-size-fits-all approach to the long-standing challenge of patient recruitment and engagement.
In a new white paper from the World Without Disease initiative, a 2024 update is provided of the current endeavours and developments that have occurred since inaugural discussions last year